-

Phreesia’s Danielle Lynch Named a ‘Sales MVP’ in PM360’s ELITE 100

RALEIGH, N.C.--(BUSINESS WIRE)--Phreesia is pleased to announce that the healthcare marketing industry trade publication PM360 has named Danielle Lynch, Vice President, Client Experience, as one of the 2022 PM360 ELITE 100.

The PM360 ELITE Awards recognize the most influential people in the healthcare and life sciences industry today, and honorees were chosen from a pool of more than 500 submissions across 20 categories. The PM360 editorial staff selected winners based on their career accomplishments and the influence they’ve had on the industry.

Lynch was named in the “Sales MVPs” category, honoring leaders who are doing an outstanding job of building revenue and forming relationships that add to the growth of their company. Since helping Phreesia go public in 2019, Lynch has played a pivotal role in more than doubling the size of her Client Experience team and its bookings.

"I'm honored to be recognized by PM360, and I'm incredibly proud of the way the Client Experience team has contributed to the growth and success of Phreesia Life Sciences over the past few years," Lynch said.

Lynch has created a positive, collaborative culture through her team-based sales model, which operates without individual contributors and instead brings in talent from creative and media agency backgrounds who have worked on a wide range of brands, therapeutic categories and life cycles to achieve its quotas. Under her leadership, the Client Experience team has grown business across almost all of its accounts, and Phreesia’s Life Sciences revenue has increased significantly, with approximately 77% expansion during fiscal year 2022.

“We are thrilled to see Danielle awarded this well-deserved honor,” said David Linetsky, Phreesia’s Senior Vice President, Life Sciences. “Her innovative approach to team building and client partnership are radically different than anything I’ve seen in other organizations. And despite rapidly scaling, she has managed to maintain the incredible team culture she pioneered to attract and retain some of the absolute best talent in the industry.”

About Phreesia Life Sciences

Phreesia empowers life sciences companies to connect meaningfully with clinically relevant patients, delivering targeted health content in a one-to-one setting. Our PatientConnect offering identifies and motivates the right patients to initiate meaningful brand conversations, and our PatientInsights product enables our clients to better understand their target patient populations.

Phreesia meets patients where they are, both virtually and in-person, and reaches them at multiple touchpoints throughout their healthcare journey. To learn more about Phreesia Life Sciences, visit lifesciences.phreesia.com.

 

Contacts

Media:
Carly Helfand
chelfand@phreesia.com
332-910-6768

Phreesia

NYSE:PHR

Release Versions

Contacts

Media:
Carly Helfand
chelfand@phreesia.com
332-910-6768

More News From Phreesia

Phreesia Named to Becker’s Hospital Review’s 2026 List of “Revenue Cycle Management Companies to Know”

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, a leader in patient intake, outreach and activation, has been named to Becker’s Hospital Review’s 2026 list of “Revenue Cycle Management Companies to Know.” The annual list recognizes companies that play a critical role in helping healthcare organizations manage the growing complexity of revenue cycle operations, including patient access, intake, billing and reimbursement. The 2026 list highlights organizations driving innovation a...

MediFind Becomes First Doctor Directory to Receive the Digital Medicine Society Seal

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--MediFind received the DiMe Seal, developed by the Digital Medicine Society, an independent nonprofit advancing the safe use of digital health....

Phreesia Announces Fourth Quarter Fiscal 2026 Results

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2026. "We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossing $100 million of Adjusted EBITDA1 and $50 million of free cash flow2 ($78.8 million net cash from operating activities) for fiscal...
Back to Newsroom